Clinical trial · Interventional
Mitochondria-targeted System Therapy Combined With Radiofrequency Ablation for Early-stage Non-small Cell Lung Cancer
Prospective Clinical Study of Mitochondria-targeted System Therapy Combined With Radiofrequency Ablation for Early-stage Non-small Cell Lung Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Lung cancer is the leading cause of cancer related mortality. Among them, non small cell lung cancer accounts for 85%. Only part of patients could be treated with radical surgery. Mitochondria-targeted system therapy combined with radiofrequency ablation could be an alternative treatment. Small sample clinical cases verified that this therapy could be an efficacy and safe treatment in a short period. The primary aim of this trial is to determine if the efficacy of mitochondria-targeted system therapy combined with radiofrequency ablation is comparable to that of standard surgical interventions for patients with non-small cell lung cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Mitochondria-targeted System Therapy Combined With Radiofrequency Ablation | Other | — | UNRESOLVED |
| Surgery | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Mitochondrial therapy with radiofrequency ablation
- interventionNames
- Other: Mitochondria-targeted System Therapy Combined With Radiofrequency Ablation
- type
- ACTIVE_COMPARATOR
- label
- Surgery
- interventionNames
- Procedure: Surgery
Primary outcomes (1)
- measure
- Disease-free survival
- timeFrame
- From the date of randomization until the date of first documented progression，assessed up to 60 months
Secondary outcomes (1)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion Criteria: * The patient can understand and voluntarily join the study, sign the informed consent form, and the compliance is good. * Patients with single nodule. * Before IIB period according to the eighth edition of the TNM staging period. * No mediastinal lymph node metastasis. * No prior anticancer treatments including surgery, radiation,chemotherapy or local treatments. * Eastern Cooperative Oncology Group performance status of 0 to 1 * Sufficient organ functions Exclusion Criteria: * Active bacterial or fungous infection. * Simultaneous or metachronous (within the past 5 years) double cancers. * Patients with contraindications to radiofrequency ablation and inability to complete treatment; * Women during pregnancy or breast-feeding. * Uncontrollable diabetes mellitus. * Patients with severe heart, lung, kidney disease or other systemic diseases who have been judged to have a severe impact on survival or who are pre-assessed to be unable to tolerate thoracoscopic surgery
References
Publications (0)
Data not yet available